illumina®

Get more from your sarcoma analysis

Detect known and novel fusion partners for fast insights with NGS

Sarcomas are rare but complex

Sarcomas are cancers found in connective tissues such as bone and soft tissues. While rare—with more than 15,000 new diagnoses each year in the US—27% are found in children and young adults under age 30.[1,2]



~1/3 of sarcomas are caused by chromosomal translocations that lead to gene fusions.[3,4]

Gene fusion partners matter

Some genes, such as *EWSR1*, are particularly associated with sarcomas and have multiple fusion partners. These varied fusion partnerships result in different sarcoma subtypes.[5]



Sarcomas include more than **50 subtypes** based on the cell of origin.[6]

Accurate subtype identification is essential for implementing insights

Detecting sarcoma subtypes is more complicated than identifying the cell of origin, but conventional molecular analysis methods can have limitations.

Fluorescence *in situ* hybridization (FISH)

- Usually interrogates only one pair of genes
- Translocations of one gene can occur with multiple fusion partners, resulting in incorrect sarcoma subtype identification

Reverse transcription polymerase chain reaction (RT-PCR)

- Requires knowledge of both partners and anticipated break points

TruSight™ RNA Fusion Panel: Comprehensive coverage in a single assay

Next-generation sequencing (NGS) covers hundreds of fusion-associated genes—and can detect novel fusions—so you can identify chromosomal abnormalities in the first try.

For Research Use Only. Not for use in diagnostic procedures.

The TruSight RNA Fusion Panel

Known and novel fusions. Fast and accurate insights.

TruSight RNA Fusion Panel covers a broad range of fusion-associated genes

>500
Fusion-associated genes

142 Fusions
previously found in sarcomas[4]

Novel Fusion Detection | without prior knowledge of specific translocations or chromosomal breakpoints

Identify fusions associated with common sarcomas

Ewing's Sarcoma | Alveolar Rhabdomyosarcoma | Synovial Sarcoma | Myxoid Liposarcoma | Other subtypes



The TruSight RNA Fusion Panel provides a reproducible and economical solution[7] for identifying gene fusions in sarcomas.

Learn More

For more information about the TruSight RNA Fusion Panel, visit illumina.com/RNAFusion.

References

1. Estimated New Cases, 2017. American Cancer Society. https://cancerstatisticscenter.cancer.org/#/data-analysis/module/BmVYeqHT?type=barGraph. Accessed June 23, 2017.
2. SEER Cancer Statistics Review 1975-2004: Table I-10, Age Distribution at Diagnosis and Death. National Cancer Institute Surveillance, Epidemiology, and End Results Program. https://seer.cancer.gov/archive/csr/1975_2004/results_merged/topic_age_dist.pdf. Accessed July 17, 2017.
3. Taylor BS, Barretina J, Maki RG, Antonescu CR, Singer S, Ladanyi M. Advances in sarcoma genomics and new therapeutic targets. *Nat Rev Cancer*. 2011;11(8):541-557.
4. Mertens F, Antonescu CR, Mitelman F, et al. Gene fusions in soft tissue tumors: Recurrent and overlapping pathogenetic themes. *Genes Chromosomes Cancer*. 2016;55(4):291-310.
5. Åman P. Fusion Oncogenes in tumor development. *Semin Cancer Biol*. 2005;15(3):236-243.
6. What is a soft tissue sarcoma? American Cancer Society. https://www.cancer.org/cancer/soft-tissue-sarcoma/about/soft-tissue-sarcoma.html. Accessed June 23, 2017.
7. Data calculations on file. Illumina, Inc. 2017.

For Research Use Only. Not for use in diagnostic procedures.

illumina®